PIK3CA

PIK3CA

A gene on chromosome 3q26.3 that encodes the 110-kDa catalytic subunit of phosphatidylinositol 3-kinase, which uses ATP to phosphorylate phosphatidylinositol, phosphatidylinositol4P and phosphatidylinositol(4,5)P2.
 
Molecular pathology
PIK3CA is oncogenic and been implicated in cervical cancers.
Mentioned in ?
References in periodicals archive ?
The cell lines created consists of the precisely engineered, disease that are associated with mutations for the most widely studied oncology genes, such as KRAS, PIK3CA and BRAF.
The first project between H3 and Precipio was the development of multiplexed PCR assays for PIK3CA and ESR1 genes.
This product received approval based on data from the phase III Solar-1 study, which indicated that Piqray plus fulvestrant nearly doubled median progression-free survival compared with fulvestrant alone in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation.
Global Banking News-May 27, 2019-Novartis awarded US FDA approval for Piqray to treat patients with PIK3CA mutation in HR+/HER2- advanced breast cancer
In addition, Zhou suggested that the mechanism of miR203 was regulating the level of ataxia telangiectasia mutated kinase-mediated-Snail and E-cadherin11, and Hao suggested that it was inducing the overexpression of PIK3CA gene.17 Although these two scholars studied the role of miR203 from different angles, they both suggest that miR203 can suppress gastric cancers.
Specimen 1 contained variants in AKT1, BRAF, FBXW7, IDH1, and KRAS; specimen 2 contained variants in EGFR and NRAS; specimen 3 contained variants in ALK, KIT, and PIK3CA. The synthetic DNA inserts contain a somatic variant with approximately 500 bp of flanking genomic sequence on each side of the variant.
In recent research, the common painkillers were found to treble the chance of survival (from 25% to 78%) for patients with a specific kind of cancer which contains an altered gene, known as PIK3CA.
The common painkillers were found to increase the chance of survival from 25% to 78% for patients whose cancer contained a specific altered gene, known as PIK3CA.
Pine's goal is to test a novel way to treat squamous cell carcinomas that have a mutation in the gene known as PIK3CA. A mutation in PIK3CA is believed to be the "driver" of this type of non-small cell lung cancer tumor.
Multiple genes have been identified with EN including RAS, FGFR3, and PIK3CA. (1) FGFR3 and PIK3CA mutations are associated with 50% of keratinocytic nevi.
Localized overgrowth syndromes such as macrodystrophia lipomatosa have been recognized as a part of overgrowth spectrum disorders related to phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) whose genotype-phenotype correlation has not been sufficiently understood (3,4).
Results from the preliminary FLAURA subgroup analysis showed that following treatment with Tagrisso in the 1st-line setting, the most frequent acquired resistance mechanisms detected in patient plasma were MET-amplification (15%) and the EGFR C797S mutation (7%), followed by HER2-amplification and the PIK3CA and RAS mutations (2-7%).